The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.
Anna BalatoAlexander ZinkGraziella BabinoDario BuononatoCharlotte KianiKilian EyerichStefanie ZiehfreundEmanuele ScalaPublished in: Life (Basel, Switzerland) (2022)
Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.
Keyphrases
- atopic dermatitis
- end stage renal disease
- disease activity
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- newly diagnosed
- systemic lupus erythematosus
- prognostic factors
- mental health
- gene expression
- dna methylation
- ankylosing spondylitis
- machine learning
- depressive symptoms
- metabolic syndrome
- adipose tissue
- patient reported outcomes
- copy number
- soft tissue
- weight loss
- genome wide
- patient reported
- quality improvement
- wound healing